Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 20, 24 | -0.17 Decreased by -70% | -0.13 Decreased by -30.77% |
| Nov 2, 23 | -0.1 Decreased by -225% | -0.13 Increased by +23.08% |
| Aug 3, 23 | -0.11 Decreased by -450% | -0.13 Increased by +15.38% |
| May 4, 23 | -0.14 Decreased by -125.93% | -0.14 |
| Feb 21, 23 | -0.1 Decreased by -152.63% | -0.01 Decreased by -900% |
| Nov 8, 22 | 0.08 Increased by +200% | 0.05 Increased by +60% |
| Aug 9, 22 | -0.02 Decreased by -100% | -0.02 |
| May 10, 22 | 0.54 Increased by +45.95% | 0.38 Increased by +42.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 9.18 M Decreased by -57.4% | -47.15 M Decreased by -57.73% | Decreased by -513.67% Decreased by -270.22% |
| Sep 30, 23 | 6.6 M Decreased by -93.49% | -28.61 M Decreased by -207.46% | Decreased by -433.55% Decreased by -1.75 K% |
| Jun 30, 23 | 10.06 M Decreased by -78.1% | -30.53 M Decreased by -349.93% | Decreased by -303.58% Decreased by -1.95 K% |
| Mar 31, 23 | 12.19 M Decreased by -96.15% | -40.11 M Decreased by -123.79% | Decreased by -328.99% Decreased by -717.84% |
| Dec 31, 22 | 21.55 M Decreased by -84.54% | -29.89 M Decreased by -149.86% | Decreased by -138.75% Decreased by -422.48% |
| Sep 30, 22 | 101.38 M Increased by +1.74 K% | 26.62 M Increased by +224.53% | Increased by +26.26% Increased by +106.77% |
| Jun 30, 22 | 45.92 M Increased by +66.11% | -6.79 M Decreased by -192.08% | Decreased by -14.78% Decreased by -75.84% |
| Mar 31, 22 | 316.58 M Increased by +56.15% | 168.57 M Increased by +43.81% | Increased by +53.25% Decreased by -7.9% |
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.